1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 22 FEBRUARY 2016

Cancer Drug News 22 FEBRUARY 2016

  • February 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Stage Set For Next Checkpoint Inhibitor Battle
Industry Trend Analysis - Ibrance Earnings Potential Unlocked Further
Industry Brief - OBI-822/821 Phase II/III Trial Fails To Meet Primary Endpoint In MBC
Industry Brief - Novartis' PKC412 Granted FDA Breakthrough Therapy Status For AML Subtype
Industry Trend Analysis - CAR-T Validation Increasing Confidence
Industry Brief - Aranesp Phase III Study Meets Primary Endpoint In MDS Patients
Industry Brief - Apogenix Secures Funding To Develop APG101 For Glioblastoma
Industry Brief - eFFECTOR Increases Funds To Advance Anti-Cancer Candidate
Industry Trend Analysis - National Cancer Moonshot Mirrors Current Oncology Trends
Industry Brief - BMS/Dana-Farber Cancer Institute Collaborate On I-O RPM Programme
Industry Brief - Myriad Collaborates With Tesaro/Merck On Companion Diagnostic Research
Industry Brief - Helsinn/Mundipharma Enter Deal For Anamorelin In Northern Europe
Industry Brief - Cancer Conferences - May 2016

Table Of Contents

Cancer Drug News 22 FEBRUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • February 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Endocrine Disease Statistics in the US

  • February 2017
    115 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Cancer Statistics in the UK

  • February 2017
    15 pages
  • Cancer  

  • United Kingdom  

View report >

Cancer Statistics

4 days ago

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.